Forskning ved Københavns Universitet - Københavns Universitet

Forside

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Alexander Klistorner
  • Yi Chai
  • Letizia Leocani
  • Philipp Albrecht
  • Orhan Aktas
  • Helmut Butzkueven
  • Tjalf Ziemssen
  • Focke Ziemssen
  • Fredriksen, Jette Lautrup
  • Lei Xu
  • Diego Cadavid
  • RENEW MF-VEP Investigators

BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.

OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.

METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.

RESULTS: A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].

CONCLUSION: Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.

REGISTRATION: ClinicalTrials.gov identifier NCT01721161.

OriginalsprogEngelsk
TidsskriftCNS Drugs
Vol/bind32
Udgave nummer12
Sider (fra-til)1159-1171
Antal sider13
ISSN1172-7047
DOI
StatusUdgivet - dec. 2018

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 209805800